Table 1 Demographics and clinical characteristics of the JME cohort.
From: Sex-specific disease modifiers in juvenile myoclonic epilepsy
Male | Female | Total cohort | |
|---|---|---|---|
N | 278 (36%) | 487 (64%) | 765 (100%) |
Age (median, range) years | 22 (9–53) | 23 (6–53) | 23 (6–53) |
Age at myoclonic seizure onset (mean ± SD) years | 14.7 ± 3.4 | 14.4 ± 3.2 | 14.5 ± 3.2 |
Absence seizures | 98 (38%) | 213 (45%) | 311 (42%) |
GTCS | 241 (90%) | 415 (88%) | 656 (89%) |
Self-reported triggered seizures | 119 (50%)* | 240 (59%)* | 359 (56%) |
Seizures triggered by stress-related precipitants | 82 (34%) | 168 (41%) | 250 (39%) |
Percentage of seizures triggered (median) | 70% | 63% | 70% |
Photosensitivity | 78 (37%)** | 206 (55%)** | 284 (49%) |
(Any) Response to photic stimulation during EEG | 69 (29%)** | 186 (44%)** | 255 (38%) |
Photoparoxysmal response | 58 (28%)** | 157 (42%)** | 215 (37%) |
Seizures triggered by photic stimulation | 28 (12%)* | 82 (20%)* | 110 (17%) |
Exclusively myoclonic seizures | 9 (32%) | 35 (43%) | 44 (40%) |
Myoclonic and other seizure types | 6 (21%) | 6 (7%) | 12 (11%) |
Other seizure types | 3 (11%) | 9 (11%) | 12 (11%) |
Unknown seizure type | 10 (36%) | 32 (39%) | 42 (38%) |
Seizure-free | 127 (71%) | 215 (66%) | 342 (68%) |
Drug-resistant | 52 (29%) | 113 (35%) | 165 (33%) |
Unknown/missing seizure control | 99 | 159 | 258 |
History of valproate use | 183 (66%)** | 222 (46%)** | 405 (53%) |
